Antigen-antibody complexes as hiv-1 vaccines

Abstract

The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention.

1 . A method of producing an immune response comprising administering to a mammal a purified antibody-antigen complex. 
     
     
         2 . The method of  claim 1 , wherein the purified antibody-antigen complex is dissociated from polyclonal anti-HIV sera bound to glycoprotein spikes on HIV envelopes. 
     
     
         3 . The method of  claim 1 , wherein the purified antibody-antigen complex dissociated from a mixture of broadly neutralizing antibodies and HIV, wherein the mixture is bound to glycoprotein spikes on HIV envelopes. 
     
     
         4 . The method of  claim 3  wherein the antibodies are monoclonal antibodies. 
     
     
         5 . The method of  claim 4  wherein the monoclonal antibodies are b12, 2F5, 2G12, 4E10, M2909 or any combination thereof. 
     
     
         5 . The method of  claim 3  wherein the HIV is a HIV clade viral isolate. 
     
     
         6 . The method of  claim 1  wherein the purified antibody-antigen complex is administered in a pharmaceutically acceptable carrier. 
     
     
         7 . The method of  claim 1  wherein the administering further comprises a prime-boost regimen. 
     
     
         8 . A method of producing an immune response comprising administering to a mammal an antibody-antigen complex, wherein the antigen is an HIV envelope protein. 
     
     
         9 . The method of  claim 8  wherein the HIV envelope protein is gp120, gp140 or a membrane associated envelope trimer. 
     
     
         10 . The method of  claim 8  wherein the antibody is a broad neutralizing antibody. 
     
     
         11 . The method of  claim 10  wherein the broad neutralizing antibody is antibody b12. 
     
     
         12 . The method of  claim 8  wherein the antibody is a non-neutralizing antibody. 
     
     
         13 . The method of  claim 12  wherein the non-neutralizing antibody is a V3 specific antibody. 
     
     
         14 . The method of  claim 13  wherein the non-neutralizing antibody is antibody 39F. 
     
     
         15 . The method of  claim 8  wherein the HIV envelope protein is a membrane associated envelope trimer and the antibody is a trimer specific antibody 2909. 
     
     
         16 . The method of  claim 8  wherein the antibody-antigen complex is administered in a pharmaceutically acceptable carrier. 
     
     
         17 . The method of  claim 8  further comprising an adjuvant. 
     
     
         18 . The method of  claim 17  wherein the adjuvant is Adjuplex LAP.